Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49

Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35

Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06

Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04

Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96

Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95

Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94

New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93

Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90

Dendritic cell-based immunotherapy for myeloid leukemias. Front Immunol (2013) 0.90

Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84

Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology (2014) 0.84

Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83

Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology (2015) 0.82

Doubling the blockade for melanoma immunotherapy. Oncoimmunology (2015) 0.80

Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers. Immunol Rev (2014) 0.80

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77

Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology (2015) 0.77

An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer. Oncoimmunology (2013) 0.76

New immunotherapeutic paradigms for castration-resistant prostate cancer. Oncoimmunology (2013) 0.75

Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75

Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75

Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82

Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood (2011) 8.26

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80

A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature (2010) 6.95

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28

Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14

Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02

Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol (2005) 4.10

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol (2012) 3.28

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res (2010) 3.02

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood (2012) 3.02

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00

What is trogocytosis and what is its purpose? Nat Immunol (2003) 2.99

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 2.97

Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79

Regulatory T cells and Foxp3. Immunol Rev (2011) 2.65

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 2.57

Myeloid-derived suppressor cells in human cancer. Cancer J (2010) 2.36

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother (2010) 2.30

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol (2011) 2.15

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res (2012) 2.14

Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08

Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06

Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med (2012) 2.04

Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 2.04

Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer (2011) 2.02

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood (2010) 2.01

Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell (2013) 2.01

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 1.92

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88

Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother (2012) 1.87

Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol (2001) 1.83

Treating cancer with genetically engineered T cells. Trends Biotechnol (2011) 1.83

Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell (2013) 1.79

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev (2011) 1.69

How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology (2012) 1.66

Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer (2010) 1.62

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res (2011) 1.62

The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med (2012) 1.61

Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60

B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58

T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood (2012) 1.55

Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J (2010) 1.52

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51

Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology (2012) 1.48

Retracted Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes. Cancer Sci (2012) 1.45

Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer (2011) 1.45

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood (2012) 1.43

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34

Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res (2012) 1.33

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33

Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res (2012) 1.32

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther (2012) 1.29

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol (2008) 1.27

Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer (1995) 1.25

OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J Immunol (2005) 1.22

Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology (2013) 1.21

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol (2012) 1.20

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19

Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18

Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17

Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res (2011) 1.13

Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol (2009) 1.13

Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09

Targeting human dendritic cell subsets for improved vaccines. Semin Immunol (2011) 1.09

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med (2012) 1.07

Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood (2012) 1.07

Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scand J Immunol (2012) 1.06

Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res (2012) 1.06

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med (2012) 1.06

The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant (2011) 1.06

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology (2012) 1.04

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01

Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol (2008) 1.00

Autophagy in the pathogenesis of disease. Cell (2008) 34.68

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47

The hallmarks of aging. Cell (2013) 14.29

Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

The pathophysiology of mitochondrial cell death. Science (2004) 13.87

Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79

Mitochondrial membrane permeabilization in cell death. Physiol Rev (2007) 12.72

Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68

ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20

Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13

Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99

Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97

Autophagy and aging. Cell (2011) 5.96

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30

Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23

Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00

Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91

Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75

Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48

Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30

Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07

The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97

The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93

Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91

Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82

Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50

Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41

Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41

Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26

Does autophagy contribute to cell death? Autophagy (2005) 3.21

A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21

Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21

AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19

Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17

Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10

BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03

A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93

Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89

The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79

Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70

Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62